REFERENCE 1 Sills ES. Conjoined twins, delivery and the memory of medicine. J R Soc Med 2005;98:135-6 Erdheim-Chester disease Dr Lee and his colleagues (April 2005 JRSM 1 ) describe a case of renal failure in which the radiographic appearance of bone pointed to Erdheim-Chester disease, a histiocytosis. Among the organs affected in this condition they mention pericardium. We think it important to emphasize the frequency with which heart, pericardium and great vessels are affected. Recording 6 new patients with cardiovascular involvement, Haroche et al. 2 have reviewed all 178 reported cases of Erdheim-Chester disease. 56% had periaortic fibrosis, 44% pericardial infiltration and/or effusions and 31% myocardial infiltration. Interestingly, 6 patients had a right atrial myxoma. Of the 58 patients with follow-up data, 31% died from cardiovascular complications.
This syndrome is caused by release of inflammatory mediators during mast cell degranulation. These compounds include preformed mediators such as histamine, neutral proteases (tryptase, chymase) and platelet activating factor and also newly synthesized mediators such as leucotrienes and thromboxane which have been incriminated clinically and experimentally in production of coronary spasm and/or acute myocardial infarction. However, inflammatory mediators have also been reported increased in the blood or urine of patients with acute coronary syndromes of non-allergic aetiology; 3-5 moreover, degranulated mast cells have been found abundant in the coronary plaque rupture areas of such patients with recent myocardial infarction. 6 For these reasons, we have suggested the existence of a final common pathway for allergic and non-allergic coronary syndromes. 7 If mast cells do contribute to non-allergic coronary events, there is scope for therapy with stabilizing drugs such as sodium cromoglicate or ketotifen and with monoclonal antibody to IgE. Experimentally, Nemmar et al. 8 have succeeded in abrogating late thrombotic events by stabilizing mast cell membrane with sodium cromoglicate and reducing inflammation with dexamethasone. We urge the research community to explore this possible final common pathway in allergic and non-allergic coronary syndromes.
